Alice Shaw, M.D., Ph.D.

Physician Investigator (Cl)
Cancer Center, Mass General Research Institute
Professor of Medicine
Harvard Medical School
Assistant In Medicine
Medicine-Hematology/Oncology, Massachusetts General Hospital
MD 1999
alk+; anaplastic lymphoma kinase; antineoplastic combined chemotherapy protocols; carcinoma non-small-cell lung; chemotherapy resistance; combination drug therapy; crizotinib; genes ras; lung cancer; lung neoplasms; non-small cell lung cancer; oncogene proteins fusion; protein kinase inhibitors; pyrazoles; pyridines; receptor protein-tyrosine kinases Alice T. Shaw, MD, PhD, is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School.  In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research.

Dr. Alice Shaw’s laboratory focuses on developing new strategies to overcome lung cancer treatment resistance – specifically for anaplastic lymphoma kinase (ALK), ROS1 and RET genetic mutations in non-small cell lung cancer (NSCLC).

By utilizing a large panel of laboratory research models that were uniquely created at Massachusetts General Hospital, Dr. Shaw and her team developed a new platform to rapidly identify drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. Using this platform, they identified several effective drug combinations, including some options that standard testing would not have predicted to work. Moreover, Dr. Shaw and her team assessed tumor biopsy samples to identify biomarkers that could predict how the patients will respond to the combination therapies. These biomarkers may greatly help doctors determine which patient will respond to the newly-discovered drug combinations. With further refinements, this strategy might be used to select the optimal treatment for each individual patient.

Since 2014, Dr. Shaw has been leading several clinical trials and translational efforts aimed at overcoming drug resistance for patients living with ALK+ NSCLC today. Previously, she was the lead investigator for the global registration studies of crizotinib (Xalkori®) and ceritinib (Zykadia®), which led to regulatory approval of both drugs in advanced ALK-rearranged NSCLC. She was also the lead investigator for crizotinib in ROS1-rearranged NSCLC.

She is now focusing new research on the most common site of metastasis for ALK+NCLC – the brain – and looking into why these tumor growths become resistant to crizotinib. Her team launched a clinical trial with the newest ALK inhibitor – lorlatinib – and they are using both tissue and liquid biopsies to identify genetic alterations that may be driving the resistance.

Lastly, since the majority of ALK+ NSCLC patients have no smoking history and do not respond to recently-approved immunotherapies like nivolumab (Opdivo®) or pembrolizumab (Keytruda®), Dr. Shaw is researching the immune microenvironment and other mutations in tumors which may underlie the low response to the new therapies.

Publications Clinical Profile

Yawkey Center Outpatient Care
32 Fruit Street
Boston, MA 02114